DOI QR코드

DOI QR Code

Isolation of Mycoplasma pneumoniae and Antimicrobial Susceptibilities of the Isolates(III)

Mycoplasma pneumoniae의 분리 및 항생제 감수성 검사(III)

  • 장명웅 (고신대학교 의과대학 미생물학교실) ;
  • 김광혁 (고신대학교 의과대학 미생물학교실) ;
  • 박인달 (고신대학교 의과대학 미생물학교실) ;
  • 송갑영 (위생병원 내과학교실) ;
  • 김성원 (고신대학교 의과대학 미생물학교실) ;
  • 이은영 (성분도병원 소아과) ;
  • 김문찬 (김문찬 소아과의원) ;
  • 조명훈 (연제 가정의학과의원) ;
  • 김규언 (연세대학교 의과대학 소아과학교실) ;
  • 최충언 (구호병원 내과, 외과, 소아과) ;
  • 박선영 ;
  • 조현장
  • Published : 2005.06.01

Abstract

The 994 throat swabs obtained from 688 adults and 306 children patients with respiratory diseases were examined for Mycoplasma pneumoniae infection by culture method. Antimicrobial susceptibilities of the resulting 123 M. pneumoniae isolates were evaluated by testing minimum inhibitory concentrations (MICs) of erythromycin, minocycline, tetracycline, josamycin, sparfloxacin, ofloxacin, and ciprofloxacin by a broth micro-dilution method. The erythromycin resistant strains of M. pneumoniae was determined above $1.0{\mu}g/ml$ of MIC for erythromycin. The erythromycin resistant strains of M. pneumoniae was confirmed resistant gene mutation of the portions of genes 23S rRNA (domain II and V), and ribosomal protein 14 and L22 by PCR amplified and their nucleotide sequenses were compared to those of the susceptible strain M129. The isolation rate of M. pneumoniae was $12.9\%$ (89/688) for the adults and $11.1\%$ (34/306) for the children. The $MICs_{90}$ of the M. pneumoniae isolates were $0.12{\mu}g/ml$ for minocycline, $0.25{\mu}g/ml$ for sparfloxacin, $0.5{\mu}g/ml$ for ciprofloxacin, ofloxacin, and tetracycline, respectively, and $2.0{\mu}g/ml$ for josamycin and erythromycin, respectively. The isolation rate of erythromycin resistant M. pneumoniae from patients was $49.4\%\;(44/89)$ for the adults, $47.1\%\;(16/34)$ for children, and $48.8\%\;(60/123)$ for the total. No mutation could be detected in the ribosomal protein L22 region, but all strains were mutated in the ribosomal protein L4 as two point mutation M144V. Two point mutations in domain V of 23S rRNA were selected in the presense of erythromycin resistant M. pneumoniae isolates, such as one strain was G2057C mutant, two strains were A2059C mutants, three strains were C2611G mutants, four strains were A2058C mutants, five strains were A2058T mutants, twenty strains were A2059G mutants, and twenty-five strains were A2058G mutants, respectively. These results show that erythromycin was not the most active compound against M. pneumoniae infection in Korea and clinical studies of macrolides in human patients are demanded.

2002년 2월부터 2005년 2월까지 성인 및 소아 호홉기질환자 994명의 상기도 도말물에서 M. pneumoniae 균주를 분리하고, 분리 균주의 ciprofloxacin, ofloxacin, minecline, tetracycline, sparfloxacin, josamycin, erythromycin에 대한 감수성 검사를 실시하였으며, 분리된 균주의 235 rRNA domain II와 V에서 erythromycin저항성 변이가 일어났는가를 PCR과 유전자 염기서열분석으로 erythromycin에 감수성인 M. pneumonine균주의 염기서열과 비교분석하여 확인하였다. 호흡기질환자에서 M. pneumoniae의 분리율은 123/994$(12.4\%)$이었으며, 분리된 M. pneumoniae 균주의 minocycline, sparfloxacin, tetracycline, ciprofloxacin, ofloxacin, josamycin, erythromycin MIC 범위는 각각 $0.015\~0.25,\;0.06\~0.5,\;0.06\~0.5,\;0.25\~0.5,\;0.25\~0.5,\;0.015\~8.0,\;0.015\~8.0{\mu}m$이었다. 분리 동정된 M. pneumoniae 균주 중에서 erythromycin에 저항성인 균주가 60주$(48.8\%)$였으며, 모두가 ribosomal protein L4 영역과 23S rRNA domain V에 내성변이가 일어났으며, 이 중 2균주는 23S rRNA domain II에도 변이가 일어난 균주도 있었다. 국내에서 분리되는 M. pneumoniae균주의 $48\%$가 erytomycin에 저항성인 균주이므로 앞으로 이 균에 의한 폐렴의 치료에 주의가 요구된다.

Keywords

References

  1. Arai S., Cohara Y., Kuwano K., Kawashima T. 1992. Antimycoplasmal activities of new quinolones, tetracyclines, and macrolides against Mycoplasma pneumoniae. Antimicrobial Agents Chemother. 36, 1322-1324 https://doi.org/10.1128/AAC.36.6.1322
  2. Arai S., Tokitsu Y. 1995. Antimycoplasmacidal activity of new quinolones in vitro and in vivo. Jap J Mycoplasmol. 21, 37-38
  3. Ban N.P., Hansen N.J., Moore P.B., Steitz T.A. 2000. The complete atomic structure of the large ribosomal subunit at 2.4 A resolution. Science 289, 905-920 https://doi.org/10.1126/science.289.5481.905
  4. Cassell C.H., Clyde W.A., and Davis J.K. 1985. Mycoplasmal respiratory infections. In The Mycoplasmas Vol. IV, Razin 5 and Barile MF (Ed), Academic Press, New York, pp65-106
  5. Chang M.W., Kim K.H., Park J.O., Joh M.H. 1995. Detection of Mycoplasma pneumoniae의in clinical specimems of patients by PCR and culture method. J Korean Soc. Microbiolo. 30, 517-525
  6. Chang M.W., Kim K.H., Park I.D., Kang K.H., Kong E.H., et al. 2003. Rapid detection of Mycoplasma pneumoniae and antimicrobial susceptibilities of the M. pneumoniae isolates. J Bacteriol Virol. 33, 183-191
  7. Daxboeck F., Krause R., Wenisch C. 2003. Laboratory diagnosis of Mycoplasma pneumoniae infection. Clin Microbiol Infect. 9(4), 263-273 https://doi.org/10.1046/j.1469-0691.2003.00590.x
  8. Doutnwaite S., Hansen L.H., Mauvis P. 2000. Macrolideketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA. Mol. Microbiol. 36, 183-192 https://doi.org/10.1046/j.1365-2958.2000.01841.x
  9. Dular R., Kajioka R., Kasatiya S. 1988. Comparison of geneprobe commercial kit and culture technique for the diagnosis of Mycoplasma pneumoniae infection. J. Clin Microbiol. 26, 1068-1069
  10. Fumeri P.M., Rappazzo G., Musumarra M.P., Dipietro P., Catania I.S., Roccasalva L.S. 2001. Two new point mutations at A2062 associated with resistance to 16-membered macrolode antibiotics in mutant strains of M. hominis. Antimicrob. Agents Chemother. 42, 2958-2960
  11. Hansen L.H., Mauvais P., Douthwaite S. 1999. The macrolide-ketolide antibiotic binding site is formed by structures in domain II and V of 23S ribosomal RNA Mol. Microbiol. 31, 623-631 https://doi.org/10.1046/j.1365-2958.1999.01202.x
  12. Jacobs E. 1993. Serological diagnosis of Mycoplasma pneumoniae infections; a critical review of current procedures. Clin Infect Dis. 17(Suppl. 1), 579-582
  13. Kaku M., Ishida K., lrifune K., Mizukane R, Takemura H., Yoshida R, et al: 1994. In vitro activities of sparfloxacin against M. pneumoniae. Antimicrobil Agents Chemother. 38, 738-741 https://doi.org/10.1128/AAC.38.4.738
  14. Kang K.S., Woo H.O. 2003. Pattern of occurrence of Mycoplasma pneumoniae pneumonia in admitted children: Southern central Korea, from 1989 to 2002. J Korean Pediatr Soc 46, 474-479
  15. Kenny G.E., Cartwright F.D. 1994. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to new glycycyclines in comparison with those to older tetracyclines. Antimicrob Agents Cjemother. 38, 2628-2632 https://doi.org/10.1128/AAC.38.11.2628
  16. Lucier T.S., Heitzman K., Liu S.K., Hu P.C. 1995. Transition mutations in the 235 rRNA of erythromycin-resistant isolates of M. pneumoniae. Antimicrob. Agents Chemother. 39, 2770-2773 https://doi.org/10.1128/AAC.39.12.2770
  17. Matsuoka M., Narita M., Okazki N., Ohya H., Yamazaki T., et al: 2004 Characterization and molecular analysis of macrolide-resistant M. pneumoniae clinical isolates obtained in Japan. Antimicrob. Agents Chemother. 48, 4624-4630 https://doi.org/10.1128/AAC.48.12.4624-4630.2004
  18. Okazaki N., Narita M., Yamada S., lzumikawa K., Umetsu M., Kenri T., Sasaki Y., Arakawa Y., Sasaki T. 2001. Characteristics of macrolide-resistant M. pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiol. lmmunol. 45, 617-620 https://doi.org/10.1111/j.1348-0421.2001.tb01293.x
  19. Pereyre S., Gonzalez P., de Barbeyrac B., Darnige A, Renaudin H., Charron A, Raherison S., Bebear C.M. 2002. Mutation in 23S rRNA account for intrinsic resistance to macrolides in M. hominis and M. fermentans and for acquired resistance to macrolides in M. hominis. Antimicrob. Agents Chemother. 46, 3142-3150 https://doi.org/10.1128/AAC.46.10.3142-3150.2002
  20. Pereyre S., Guyot C., Renaudin H., Charron A, Bebear C., Bebear c.M. 2004. In vitro selection and characterization of resistance to macrolides and related antibiotics in M. pneumoniae. Antimicrob. Agents Chemother. 48, 460-465 https://doi.org/10.1128/AAC.48.2.460-465.2004
  21. Prunier A.J., Malbrunny B., Tande D., Picard B., Leclercq R 2002. Clinical isolates of Staphylococcus aureus with ribosomal mutations conferring resistance to macrolides. Antimicrb. Agents Chemother. 46, 3054-3065 https://doi.org/10.1128/AAC.46.9.3054-3056.2002
  22. Schulunzen F., Zarivach R, Harms J., Bashan A., Todlj A., Albercht R., Yonath A, Franceschi F. 2001. Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature 413, 814-821 https://doi.org/10.1038/35101544
  23. Suyama N., Ishida K., Kaku M., Izumikawa K., Hara K. 1995. Therapeutic activites of macrolides against M. pneumoniae infection. Jap J Mycoplasmol. 21, 39-40
  24. Tully J.G., Rose D.L. 1979. Enhanced isolation of Mycoplasma pneumoniae from throat washings with a newly modified culture medium. J Infect Dis. 139, 478-482 https://doi.org/10.1093/infdis/139.4.478
  25. Vester B., Douthwaite S. 2001. Macrolide resistance conferred by base substitution in 23S rRNA. Antimicrob. Agents Chemother. 45, 1-12 https://doi.org/10.1128/AAC.45.1.1-12.2001
  26. Waites K.B., Duffy L.B., Schmid T., Carb D., Pate M.S, Cassell GH: 1991. In vitro susceptibilities of Mycoplasma pneumoniae, M. hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391. Antimicrobial Agents Chemother. 35, 1181-1185
  27. Weisblum B. 1995. Erythromycin resistance by ribosome modification. Antimicrob. Agents Chemother. 39, 577-585 https://doi.org/10.1128/AAC.39.3.577
  28. Yamaguchi T., Hirakata Y., lzumikawa K., Miyazaki Y., Maesaki S., et al: 2000. In vitro activity of telithromycin (HMR3647), a new ketolide, against clinical isolates of M. pneumoniae in Japan. Antimicrob. Agents chemother. 44, 1381-1382 https://doi.org/10.1128/AAC.44.5.1381-1382.2000

Cited by

  1. Multi-drug Resistance of Mycoplasma pneumoniae Isolates from Patients with Respiratory Diseases against Quinolone and Macrolide vol.17, pp.3, 2007, https://doi.org/10.5352/JLS.2007.17.3.435
  2. Mycoplasma pneumoniaePneumonia Unresponsive to Macrolide Treatment vol.2, pp.4, 2012, https://doi.org/10.3343/lmo.2012.2.4.226
  3. Usefulness of Pleural Adenosine Deaminase in Children for the Differentiation Tuberculous Pleural Effusion fromMycoplasma pneumoniawith Pleural Effusion vol.22, pp.4, 2012, https://doi.org/10.7581/pard.2012.22.4.404
  4. in comparison with viral pneumoina in children: A multicenter, cross-sectional study vol.6, pp.3, 2018, https://doi.org/10.4168/aard.2018.6.3.155